Lianhong Xinke announced that in order to speed up the strategic layout, the company plans to increase the capital of the holding subsidiary Academy of Sciences Biotech with 150 million yuan of its own capital, and that other shareholders will not increase their capital at the same time. This transaction constitutes a related transaction and does not constitute a major asset restructuring. Academy of Sciences Biotech's 2024 revenue was 4,836 million yuan, net profit was 2,2296 million yuan, revenue for the first three quarters of 2025 was 52.8966 million yuan, and net profit was 15.7672 million yuan. After the capital increase, the company's shareholding ratio will increase from 51% to 65.7%. The company shall pay within 20 working days of signing the agreement, and Academy of Sciences Biotech will complete the commercial and commercial changes within 20 working days of receipt of payment.

Lianhong Xinke announced that in order to speed up the strategic layout, the company plans to increase the capital of the holding subsidiary Academy of Sciences Biotech with 150 million yuan of its own capital, and that other shareholders will not increase their capital at the same time. This transaction constitutes a related transaction and does not constitute a major asset restructuring. Academy of Sciences Biotech's 2024 revenue was 4,836 million yuan, net profit was 2,2296 million yuan, revenue for the first three quarters of 2025 was 52.8966 million yuan, and net profit was 15.7672 million yuan. After the capital increase, the company's shareholding ratio will increase from 51% to 65.7%. The company shall pay within 20 working days of signing the agreement, and Academy of Sciences Biotech will complete the commercial and commercial changes within 20 working days of receipt of payment.